A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability

mRNA vaccines were the first to be authorized for use against SARS-CoV-2 and have since demonstrated high efficacy against serious illness and death. However, limitations in these vaccines have been recognized due to their requirement for cold storage, short durability of protection, and lack of acc...

Descripción completa

Detalles Bibliográficos
Autores principales: Voigt, Emily A., Gerhardt, Alana, Hanson, Derek, Jennewein, Madeleine F., Battisti, Peter, Reed, Sierra, Singh, Jasneet, Mohamath, Raodoh, Bakken, Julie, Beaver, Samuel, Press, Christopher, Soon-Shiong, Patrick, Paddon, Christopher J., Fox, Christopher B., Casper, Corey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9628444/
https://www.ncbi.nlm.nih.gov/pubmed/36323666
http://dx.doi.org/10.1038/s41541-022-00549-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9628444/
https://www.ncbi.nlm.nih.gov/pubmed/36323666
http://dx.doi.org/10.1038/s41541-022-00549-y

Ejemplares similares